Report Highlights
The global influenza market was valued at nearly $5.6 billion in 2017 and is expected to reach nearly $6.5 billion by 2022, increasing at a compound annual growth rate (CAGR) of 3.0% from 2017 through 2022.
Report Includes
- 25 data tables and 77 additional tables
- An overview of the global influenza market
- Analyses of global market trends, with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022
- Identification of segments with high growth potential and their future applications
- Discussion on the role of major vaccine providers and companion products approved for a wide variety of influenza testing platforms, including adenovirus, SARS, parainfluenza, coronavirus, human metapneumovirus (hMPV) and others
- Explanation of major drivers and regional dynamics of the market and current trends within the industry
- Detailed profiles of major vendors in the market, including Alere, MedImmune, Cepheid, GlaxoSmithKline and Qiagen.
Report Scope
This BCC Research report is designed to be a helpful business tool that provides a thorough evaluation of the market for influenza vaccines, therapeutics and diagnostics. The geographic scope of this study is global, with emphasis on U.S. and European data. The report identifies markets in general segments: Vaccines, Therapeutics and Diagnostics. Each market segment discussion provides detailed information based on product categories, uses of products, forecasts and competitive analyses. Additionally, the study covers some of the most significant issues, trends and market factors.
Analyst Credentials
Melissa Elder is an experienced healthcare market analyst specializing in medical treatments, equipment and devices. Ms. Elder holds an MBA in Health Care Management and provides consultation to various institutions globally. She has been involved in the healthcare industry since 1996, providing more than 23 years of industry expertise. Ms. Elder has specialized in market research for more than 20 years, focusing on the areas of advanced medical technologies, biological products and animal health. In-depth analysis into more than 100 health-related topics has given Ms. Elder substantial insight into industry dynamics, market influences and future direction of various health markets. Her work in the medical community, including emergency room medical training and healthcare information system coordination, has enhanced her ability to provide insight into many healthcare specialties. She has authored several industry-specific documents and is a well-respected contributor to the market research community. Her writings are published in magazines, newspapers and professional journals. She is also an experienced custom market research writer who has worked with a large variety of clients in many fields who require innumerable variations to research documents.
Report Highlights
The global influenza market reached $5.1 billion in 2015. This market is expected to increase from $5.4 billion in 2016 to $6.4 billion in 2021 at a compound annual growth rate (CAGR) of 3.6% for 2016-2021.
Report Includes
- An overview of the global market for influenza vaccines, therapeutics, and diagnostics.
- Analyses of global market trends, with data from 2015 and 2016, and projections of compound annual growth rates (CAGRs) through 2021.
- Information about products available, products in development, issues and trends influencing the market, and competitive analysis of top providers, with a special emphasis on U.S. and European markets.
- Discussion of efforts by government agencies and disease prevention organizations to support and fund research and development programs, and pandemic prevention.
- Analysis of the market's dynamics, specifically growth drivers, restraints, and opportunities.
- Profiles of major players in the industry.
Report Highlights
The global influenza market will grow from nearly $3.8 billion in 2012 to $4 billion in 2013. Market revenue is forecast to increase at a five-year compound annual growth rate (CAGR) of 8% from 2013 to 2018, totaling nearly $6 billion in 2018.
Report Includes
- An overview of the global market for influenza vaccines, therapeutics, and diagnostics.
- Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) for the period 2013 and 2018.
- Information about products available, products in development, issues and trends influencing the market, and competitive analysis of top providers, with a special emphasis on U.S. and European markets.
- Discussion of efforts by government agencies and disease prevention organizations to support and fund research and development programs, and pandemic prevention.
- Comprehensive company profiles of major players.
Report Highlights
- Overall sales in the global influenza market were worth $5.3 billion in 2007, which declined to $3.7 billion in 2008, then increased to an estimated $5.5 billion in 2009. By 2014, it is projected to increase to $6.3 billion, for a 5-year CAGR of 2.7%.
- The largest segment of the market, vaccines, was valued at $2.8 billion in 2008; this is expected to increase to $3.2 billion in 2009, and is projected to reach $4.2 billion in 2014, for a 5-year CAGR of 5.6%.
- Sales in the therapeutics market amounted to $701 million in 2008, increased to an estimated $2.1 billion in 2009, and are expected to fall to $1.9 billion in 2014, for a 5-year CAGR of -2.4%.
Report Highlights
- By 2010, the worldwide influenza market is likely to reach $7.1 billion, with average annual growth estimated at 19.8%.
- The worldwide influenza market is estimated at $2.9 billion in 2005, up from $1.5 billion the previous year.
- The market is estimated to reach $7.1 billion in 2010, an increase of more than $4.2 billion over the forecast period.
- The worldwide therapeutics/vaccines market is likely to reach $6.9 billion in 2010, with average annual growth estimated at 20.8%.
Related Reports
Global Markets for Vaccine Technologies
The global market for vaccine technologies is expected to grow from $45.0 billion in 2023 to $65.3 billion by the end of 2028, at a compound annual growth rate (CAGR) of 7.8% from 2023 to 2028.
Global Markets for Generic Drugs
The global market for generic drugs is expected to grow from $435.3 billion in 2023 and projected to reach $655.8 billion by the end of 2028, at a compound annual growth rate (CAGR) of 8.5% from 2023 to 2028.
Polymerase Chain Reaction (PCR) Technologies and Global Markets
The global market for polymerase chain reaction (PCR) is estimated to increase from $9.1 billion in 2023 to reach $12.6 billion by 2028, at a compound annual growth rate (CAGR) of 6.7% from 2023 through 2028.
Global Markets for Animal Therapeutics and Diagnostics
The global market for animal therapeutics and diagnostics is estimated to increase from $61.0 billion in 2023 to reach $81.2 billion by 2028, at a compound annual growth rate (CAGR) of 5.9% from 2023 through 2028.
Recent Reports
Drugs and Diagnostics for Hematological Disorders: Global Markets
The global market for drugs and diagnostics for hematological disorders is expected to grow from $131.2 billion in 2024 and is projected to reach $189.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.6% during the forecast period of 2024 to 2029.
Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets
The global market for gastrointestinal (GI) therapeutics and diagnostics is expected to grow from $86.0 billion in 2023 and projected to reach $122.5 billion by the end of 2028, at a compound annual growth rate (CAGR) of 7.3% during the forecast period of 2023 to 2028.
Global Markets and Technologies for Advanced Drug Delivery Systems
The global market for advanced drug delivery systems is expected to increase from $262.6 billion in 2023 to $359.1 billion by the end of 2028, with a compound annual growth rate (CAGR) of 6.5% during the forecast period of 2023-2028.
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets
The global market for prostate cancer care is expected to grow from $37.9 billion in 2023 to $56.4 billion by the end of 2028, at a compound annual growth rate (CAGR) of 8.3% from 2023 through 2028.
Chagas Disease: American trypanosomiasis Market
The report provides detailed coverage of the Chagas Disease market. It analyzes the market trends and epidemiology of CD, and the regional markets of CD. It highlights the current market for CD and gives a detailed analysis of the competitive environment. The report depicts the complete scenario of Chagas Disease, types of parasites that cause human African trypanosomiasis (HAT) and its presence in various regions of the world.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More